TABLE 7.
Dose proportionality of EIDD-1931a
| Parameterb | Day 1 |
Day 6 |
||||||
|---|---|---|---|---|---|---|---|---|
| nc | Slope (90% confidence interval) | Between-subject geometric coefficient of variation | Lack of fit P value | n | Slope (90% confidence interval) | Between-subject geometric coefficient of variation | Lack of fit P value | |
| AUCinf (ng · h/ml) | 53 | 1.10 (1.06, 1.14) | 19.6 | 0.3149 | ||||
| AUClast (ng · h/ml) | 54 | 1.11 (1.07, 1.15) | 20.8 | 0.4483 | ||||
| AUCτ (ng · h/ml) | 41 | 1.08 (1.02–1.14) | 20.5 | 0.3670 | ||||
| Cmax (ng/ml) | 54 | 0.957 (0.916, 0.998) | 20.1 | 0.7011 | 41 | 0.971 (0.915–1.03) | 20.3 | 0.7798 |
a
50 to 1,600 mg molnupiravir, single ascending doses (day 1), and 50 to 800 mg molnupiravir, twice-daily multiple ascending doses (day 6).
b
AUCτ, area under the plasma concentration-time curve during a dosing interval; AUCinf, area under the plasma concentration-time curve from time zero extrapolated to infinity; AUClast, area under the plasma concentration-time curve from time zero to the last measurable nonzero concentration; Cmax, maximum observed concentration.
c
n, number of observations.